Rociletinib

Rociletinib

Clinical data
Routes of administration	By mouth
ATC code	L01XE37 (WHO)
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-(3-{[2-{[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino}-5-(trifluoromethyl)-4-pyrimidinyl]amino}phenyl)acrylamide
Synonyms	CO-1686, AVL-301
CAS Number	1374640-70-6
PubChem CID	57335384
ChemSpider	30646712
UNII	72AH61702G
KEGG	D10858
Chemical and physical data
Formula	C27H28F3N7O3
Molar mass	555.56 g·mol−1
3D model (Jmol)	Interactive image
SMILES CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F
InChI InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35) Key:HUFOZJXAKZVRNJ-UHFFFAOYSA-N

Rociletinib (INN) is a drug for the treatment of non-small cell lung cancer, acting as an inhibitor of the epidermal growth factor receptor (EGFR). It was being developed by Clovis Oncology. According to the company web site as of November 2016, development was halted and studies on the drug are no longer accepting new patients, but Clovis will continue to supply the drug to patients whose physicians had recommended continued treatment.